Leukodystrophy Hypomyelinating 7 With Or Without Oligodontia And Or Hypogonadotropic Hypogonadism Cn034185
A rare genetic disorder affecting the brain's white matter and myelin. Children develop neurological problems including movement difficulties and developmental delays. Treatment focuses on supportive care and managing symptoms.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Motor developmental delay
(neurologic)Ataxia
(neurologic)Spasticity
(neurologic)Hypogonadotropic hypogonadism
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Multidisciplinary Developmental Support
Comprehensive physical and occupational therapy program addressing motor delays, muscle tone abnormalities, and promoting functional independence. Early intervention services are crucial for maximizing developmental potential.
Seizure Management
Anticonvulsant therapy for patients experiencing seizures, which are common in hypomyelinating leukodystrophies. Choice of agent based on seizure type and side effect profile.
Additional treatment options
Neurological Progression Tracking
Regular neuroimaging and neurological examinations to track disease progression, assess white matter changes, and guide therapeutic decisions.
monitoringNeuropsychological Support
Cognitive and behavioral support services addressing learning difficulties, attention deficits, and emotional regulation challenges common in children with leukodystrophies.
psychologicalEndocrine Evaluation and Management
Assessment and treatment of hypogonadotropic hypogonadism if present, including hormone replacement therapy and monitoring of puberty development and bone health.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Leukodystrophy Hypomyelinating 7 With Or Without Oligodontia And Or Hypogonadotropic Hypogonadism Cn034185?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Leukodystrophy Hypomyelinating 7 With Or Without Oligodontia And Or Hypogonadotropic Hypogonadism Cn034185. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy